<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617942</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG-BR-211B</org_study_id>
    <nct_id>NCT00617942</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer</brief_title>
  <official_title>BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Sikov MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Q3week carboplatin with weekly abraxane and trastuzumab as neoadjuvant therapy in resectable
      and unresectable HER2+ (stage IIa-IIIb) breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our goal is to develop an induction chemotherapy regimen that will have a pCR rate above 50%
      in HER2+ patients without exposing patients to the toxicity of an anthracycline-based
      regimen. A minimum of 60 evaluable patients will be accrued to the study. We are assuming an
      observed pCR (or near pCR) rate of 70%. Assuming no more than 10% of patients will be
      inevaluable for the primary endpoint (pCR), we will have at least 54 evaluable patients. With
      this number, we will have 90% power, with a 1-sided alpha error of 0.05, to demonstrate a pCR
      rate exceeding 50% for our novel regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and Unresectable LABC;</measure>
    <time_frame>1 year</time_frame>
    <description>These numbers represent patients with a RCB score of zero (0). RCB stands for residual cancer burden.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients Affected by Toxicities of Regimen During Treatment, Including Grade &gt;2 Neurotoxicity the Incidence of Subclinical and Clinical Cardiac Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Please note that these events represent toxicities that were experienced during treatment, but that does not mean that all toxicities were indeed deemed related to study treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neo-adjuvant cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neo-adjuvant cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1 neo-adjuvant</intervention_name>
    <description>Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14
Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16</description>
    <arm_group_label>Neo-adjuvant cohort 1</arm_group_label>
    <other_name>Abraxane (nab-paclitaxel), Herceptin (trastuzumab) and carboplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2 neo-adjuvant</intervention_name>
    <description>Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16</description>
    <arm_group_label>Neo-adjuvant cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1 adjuvant</intervention_name>
    <description>Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians</description>
    <arm_group_label>Adjuvant cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2 adjuvant</intervention_name>
    <description>Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians</description>
    <arm_group_label>Adjuvant cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented adenocarcinoma of the breast

          -  ANC &gt; 1000 cells

          -  Female; age &gt; 18; Zubrod PS 0-1

          -  Platelets &gt; 100,000

          -  Stage IIA-IIIB disease

          -  Total bilirubin &lt; or = ULN

          -  No evidence of metastatic disease Not pregnant or lactating

          -  No prior systemic therapy for this breast cancer

          -  Serum Creatinine &lt; 1.5 mg/dl or Creat Cl &gt; 30 ml/min

          -  Serum ALT &lt; 2.5 x ULN

          -  ER, PR and HER2 status required

          -  LVEF (MUGA/echo)WNL

          -  No baseline &gt; 2 neuropathy

          -  Hemoglobin &gt; 9.0 gm/dl

          -  HER2+, defined by IHC 3+ or FISH ratio &gt; 2.0
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Sikov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Smilow Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Williams Medical Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island and The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <results_first_submitted>November 14, 2015</results_first_submitted>
  <results_first_submitted_qc>July 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2017</results_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>William Sikov MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Cohort 1 neo-adjuvant: Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14
Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
Cohort 1 adjuvant: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Cohort 2 neo-adjuvant: Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
Cohort 2 adjuvant: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.4" lower_limit="32" upper_limit="72"/>
                    <measurement group_id="B2" value="51.6" lower_limit="35" upper_limit="70"/>
                    <measurement group_id="B3" value="51.5" lower_limit="32" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and Unresectable LABC;</title>
        <description>These numbers represent patients with a RCB score of zero (0). RCB stands for residual cancer burden.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and Unresectable LABC;</title>
          <description>These numbers represent patients with a RCB score of zero (0). RCB stands for residual cancer burden.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Affected by Toxicities of Regimen During Treatment, Including Grade &gt;2 Neurotoxicity the Incidence of Subclinical and Clinical Cardiac Toxicity</title>
        <description>Please note that these events represent toxicities that were experienced during treatment, but that does not mean that all toxicities were indeed deemed related to study treatment.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neo-adjuvant Cohort 1</title>
            <description>Cohort 1 neo-adjuvant: Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14
Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16</description>
          </group>
          <group group_id="O2">
            <title>Neo-adjuvant Cohort 2</title>
            <description>Cohort 2 neo-adjuvant: Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16</description>
          </group>
          <group group_id="O3">
            <title>Adjuvant Cohort 1</title>
            <description>Cohort 1 adjuvant: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians</description>
          </group>
          <group group_id="O4">
            <title>Adjuvant Cohort 2</title>
            <description>Cohort 2 adjuvant: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Affected by Toxicities of Regimen During Treatment, Including Grade &gt;2 Neurotoxicity the Incidence of Subclinical and Clinical Cardiac Toxicity</title>
          <description>Please note that these events represent toxicities that were experienced during treatment, but that does not mean that all toxicities were indeed deemed related to study treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Toxicities were captured at start of treatment through 1 year of adjuvant trastuzumab. CTCAE version 3.0 was used.</time_frame>
      <desc>Please note that all AEs are reported here but this does not mean that all toxicities were deemed related to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Neo-adjuvant Cohort 1</title>
          <description>Cohort 1 neo-adjuvant: Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14
Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16</description>
        </group>
        <group group_id="E2">
          <title>Neo-adjuvant Cohort 2</title>
          <description>Cohort 2 neo-adjuvant: Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16</description>
        </group>
        <group group_id="E3">
          <title>Adjuvant Cohort 1</title>
          <description>Cohort 1 adjuvant: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians</description>
        </group>
        <group group_id="E4">
          <title>Adjuvant Cohort 2</title>
          <description>Cohort 2 adjuvant: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>gr 3port infection,</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>gr 4 sepsis, intubated</sub_title>
                <description>neutro 3, anemia 3, thromb 4, HTN 4, arf 3, hypok 4, hypocal 4, ards 4, hyperbili 3, tach 4, fever 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea gr 2, Nausea gr 3, infection gr 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>infection normal ANC/viral grade 1</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dehydration 3, Diarrhea 3, Vomit 3, HGB3, Nausea 3, K 3, Dyspnea 2</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>gr 3cellulitis - breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>gr 3 diarrhea, gr 2 neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>UTI, gr 3 ANC, gr 3 HGB, Gr3 infection, Gr 2 fever and pain, gr1 rigor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>fever unknown etiology gr 1, lymphatics gr 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Syncopal epidose gr 3, dehydration gr 2, diabetes gr 2, anemia gr 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>thrombus occlusive L IJ gr 3, hypomagnesia gr 1, hypokalemia gr 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>dehydr gr3, chest pain gr 3,</sub_title>
                <description>Hypotension gr 2, HGB gr 3, Fever gr2, creatinine gr 1, diarrhea gr 2, infection gr 3, ANC gr 3,</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>gr 3 left jugular thrombis , anemia gr 2,</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>left ear otitis externa gr 3, ANC 4, WBC 2 Diarrhea 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>vomit gr 3, Nausea gr 3, diarrhea gr2, GI bleed gr 2, Abdominal pain rg3,</sub_title>
                <description>hgb gr 2, Na 1, K 1, Ca 1, ANC 2, Anorexia 3,dehydration gr3, cr gr 1, WBC gr 2,</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>vomiting gr 3, infection Cdiff gr 3, Hypokalemia gr 1, gr 1 hypomagnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>right upper extremity cellulitis gr 3,</sub_title>
                <description>right ue pain gr 2, UTI gr 2, WBC gr 2, HGB gr 2, ANC gr 2, K gr 2, hypoalbum gr 1, INR gr 1, constipation gr 1,</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>gr 3 ulcerative colitis exacerbation with and without gr 1 fever)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>gran mal seizure-2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>allergic rxn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia gr 2, Anemia 2, ANC 4,</sub_title>
                <description>External ear inflammation 1, tachycardia 1, PLT 1, Myalgias 2</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>suicidal ideation gr 2 and depression gr 3 not related</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>post re-construction pt experienced seroma grade 2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hernia grade 3 secondary to surgery healing issue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sepsis 3, PLT 1, K, 1, Ca, 1, Hgb1, Phos, 3, Pruritis, 1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cardiac ischemia gr 2,</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>gr 3 abd pain, gr 1 nausea, gr 2 vomitting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>impt medical event(gr2) abnormal stress test need for cardiac cath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WBC</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="37"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>ANC</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="37"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="23"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>plt</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="37"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>HGB</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="37"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="23"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="29"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>M/A</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>creatinine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>wt loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="37"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="29"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="37"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>AST/ALT</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="37"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="29"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neurosensory</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neuromuscular</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>K</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="37"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mg</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="37"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ca</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Phos</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>HTN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abd pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>tinnuitius</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>wt gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>ocular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>rectal bleed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>glucose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>rigors</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>troponin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>SOB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>desquam skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>glucose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>DVT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>pain breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>mood alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>chelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>albumin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>hypouricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Sikov, MD</name_or_title>
      <organization>Brown University Oncology Research Group (BrUOG)</organization>
      <phone>4018633000</phone>
      <email>kayla_rosati@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

